The compounded GLP-1 market thrived because it solved a problem the brand-name market refused to address: cost. When Wegovy listed at $1,349/month and insurance coverage was limited, compounding pharmacies offered semaglutide at $150–$300/month. At peak volume in 2024, compounded versions accounted for roughly 30% of total U.S. GLP-1 supply.
That market is now under regulatory siege. The FDA resolved both the semaglutide and tirzepatide shortages. The April 30, 2026 proposal to exclude these substances from the 503B bulks list would eliminate the remaining legal pathway for large-scale compounding. Whether or not the exclusion is finalized, the direction is clear: the $150/month compounded semaglutide era is ending.
The question for patients is: what fills the gap?
The 2026 Pricing Landscape
The good news is that brand-name GLP-1 pricing has moved significantly since the days when compounding was the only affordable option. Here is what the current landscape looks like:
| Access Path | Monthly Cost | What You Get |
|---|---|---|
| Medicare GLP-1 Bridge | $50/mo | Wegovy (injectable + tablet), Zepbound KwikPen, Foundayo. Part D required. Starts July 2026. |
| Oral Wegovy (self-pay) | $149–$299/mo | Starting dose at $149/mo. Maintenance dose up to $299/mo. No injection needed. |
| LillyDirect (Zepbound) | ~$399/mo | Brand-name tirzepatide via direct-to-consumer program. Self-pay. |
| Wegovy injectable (DTC discount) | $199–$399/mo | Manufacturer savings offer. Price varies by dose. |
| Telehealth + brand-name Rx | $250–$500/mo | Varies by provider. Includes consultation + brand-name prescription. |
| Compounded (503A, where legal) | $150–$350/mo | Patient-specific Rx. Limited formulations. Legal uncertainty. |
| Insurance (commercial) | $25–$100/mo copay | Increasingly covered for obesity. Prior auth usually required. |
| Full retail (no discount) | $1,000–$1,349/mo | Wegovy or Zepbound at list price. Rare — most patients use some discount. |
The Pricing Pressure Is Working
One of the under-appreciated effects of the compounding market is that it forced brand-name manufacturers to compete on price. Eli Lilly's LillyDirect program at $399/month, Novo Nordisk's self-pay Wegovy pill at $149/month starting dose, and the manufacturer discount programs all exist in part because compounded alternatives demonstrated that patients would pay $150–$300 but not $1,300.
Even as compounding contracts, the pricing pressure it created has permanently lowered the ceiling for what manufacturers can charge self-pay patients. The $1,349 list price for Wegovy still exists, but the number of patients actually paying it has shrunk dramatically.
Insurance Coverage Is Expanding
The biggest long-term shift is employer-sponsored insurance coverage for obesity treatment. Several major employers and insurers have added GLP-1 medications to their formularies for weight management in 2025 and 2026, driven by accumulating data on cardiovascular benefits (SELECT trial) and the business case for treating obesity as a chronic disease rather than a lifestyle choice.
If your employer offers health insurance, it is worth checking whether GLP-1 medications for weight management are now covered. Plans that excluded them in 2024 may have added them in 2025 or 2026. A prior authorization will likely be required, and approval rates vary, but the trend is moving in patients' favor.
What Happens If the 503B Exclusion Finalizes
If the FDA finalizes the exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the large-scale compounding supply chain shuts down. The telehealth platforms that built their business on low-cost compounded GLP-1 prescriptions will need to pivot to brand-name formularies.
Several of these platforms have already begun the transition. Ro, LifeMD, and Weight Watchers have partnerships with brand-name manufacturers. Some telehealth providers are repositioning around oral Wegovy, which offers a lower price point ($149/month for the starting dose) than injectable alternatives.
For patients currently using compounded GLP-1s, the transition will likely mean higher out-of-pocket costs — but the gap between compounded and brand-name pricing has narrowed substantially compared to even a year ago.
Action Steps for Current Compounded Users
Check your insurance now. Coverage for GLP-1 weight management medications has expanded in 2025–2026. Contact your insurer's pharmacy benefit department and ask specifically about coverage for Wegovy or Zepbound for weight management, not just diabetes.
Evaluate the Medicare Bridge. If you are a Medicare Part D beneficiary, the $50/month Bridge program launches July 1, 2026. This may be the most affordable option available.
Ask your telehealth provider about their brand-name options. Many platforms now offer brand-name prescriptions alongside or instead of compounded products. The pricing may surprise you — it is lower than list price in almost every case.
Consider oral semaglutide. The Wegovy pill is available at $149/month for the starting dose. If you are transitioning from compounded semaglutide and want to stay with semaglutide, the oral formulation may be the most direct replacement at a comparable price point.
Plan ahead. Do not wait until your compounded supply is disrupted to explore alternatives. Start investigating your options now so you can transition without a gap in treatment.
Compare Your Options
See which telehealth providers offer brand-name GLP-1 prescriptions, what they cost, and which accept insurance — all in one place.
Compare Providers